Scientific deep-dive

Zepbound Hair Loss: How to Stop It and What the Label Says (2026)

Zepbound's label lists hair loss in 4–5% of users vs 1% on placebo, mostly women. How to stop it, why a lower dose may not help, and when to see a doctor.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
11 min read·12 citations

You usually can’t switch off Zepbound hair loss once it has started, but it tends to stop on its own when your weight levels off, and the steps that help are about not making it worse: eat enough protein, don’t lose faster than you need to, and get blood tests before buying supplements. The ZEPBOUND prescribing information says hair loss on the drug “was associated with weight reduction,” puts the rate at 4% to 5% across all three maintenance doses versus 1% on placebo, and shows it was far more common in women (7.1%) than men (0.5%)[1]. In the same trials no patient taking Zepbound stopped treatment because of hair loss[1].

The short version for Zepbound users: the shedding most people notice a few months in is usually telogen effluvium, a reaction to rapid weight loss, and a pattern patients describe again and again in Reddit threads on GLP-1 hair loss. A lower dose is not a proven fix, because the label shows almost the same hair-loss rate at 5 mg as at 15 mg. Stopping Zepbound on your own is also a poor trade: in SURMOUNT-4, people switched to placebo regained 14% of their weight within a year[4]. Talk to your prescriber about pace, protein and labs instead.

How to stop Zepbound hair loss: what actually helps

No treatment has been tested specifically for shedding on tirzepatide. A 2026 dermatology commentary on GLP-1 hair loss notes that no prospective controlled studies have looked at the problem at all[8]. What follows is what the label, the trials and dermatology guidance support, ranked by how much you can do about it.

  1. Keep taking it unless your prescriber says otherwise. The label reports zero Zepbound discontinuations for hair loss[1], and the dermatology commentary’s view is that in telogen effluvium “the hair loss will stop after the weight loss stops”[8]. Quitting mid-course trades a temporary cosmetic problem for regain: in SURMOUNT-4, weight rose 14.0% in the year after people switched to placebo, while those who stayed on tirzepatide lost a further 5.5%[4].
  2. Ask about pace, not just dose. The same commentary says dose reduction can be considered when hair loss appears[8], but Zepbound’s own numbers give little reason to expect a step down from 15 mg to 10 mg to help: 10 mg ran at 4% and 15 mg at 5%[1]. What a prescriber can adjust is how quickly you climb the dose ladder. The label allows 2.5 mg increases every at least 4 weeks, so staying longer on a step is within the label[1].
  3. Eat enough, especially protein. Crash dieting and low protein intake are both listed triggers of telogen effluvium[7], and Zepbound’s appetite suppression can push intake well below what you planned. In a SURMOUNT-1 body-scan substudy, about a quarter of the weight people lost on tirzepatide was lean mass[5]. Our GLP-1 protein calculator turns your weight into a daily gram target, and resistance training protects the lean side of the ledger.
  4. Test, then supplement. Iron deficiency and an underactive thyroid are recognized triggers[7], so heavy shedding is a reason to ask for a blood panel. But don’t assume a deficiency: in a case-control study of 90 women with chronic telogen effluvium, ferritin, B12, vitamin D, thyroid tests and biotin did not differ from controls (only zinc was lower), and the authors concluded deficiencies are “not as common as thought”[9]. See iron and ferritin on GLP-1s for what the iron numbers mean.
  5. Skip high-dose biotin unless a test says you need it. A systematic review of biotin for hair found that every reported success involved an underlying deficiency or disorder, and concluded there is not enough evidence to supplement healthy people[10].
  6. If it isn’t telogen effluvium, treat what it is. Weight loss can make pattern thinning more visible. Minoxidil and finasteride are covered in our treatment evidence review.

What the Zepbound label says about hair loss

Hair loss is on the label’s list of most common adverse reactions, the ones reported in at least 5% of Zepbound patients[1]. The numbers come from a pooled safety analysis of the two placebo-controlled 72-week weight-reduction trials: SURMOUNT-1 (adults with obesity, no diabetes)[2] and SURMOUNT-2 (adults with obesity and type 2 diabetes)[3].

Hair loss and weight change by Zepbound dose. Hair-loss rates are from the label's pooled SURMOUNT-1 + SURMOUNT-2 safety table; weight change is SURMOUNT-1 at week 72.
PlaceboZepbound 5 mgZepbound 10 mgZepbound 15 mg
Hair loss (label pool)[1]1%5%4%5%
Patients in safety pool958630948941
Mean weight change (SURMOUNT-1)[1][2]−3.1%−15.0%−19.5%−20.9%

Two details in that table matter for anyone hoping a dose change will fix things. First, the hair-loss rate is essentially flat from 5 mg to 15 mg even though average weight loss climbs from 15% to 21%. Second, the 5 mg column comes entirely from SURMOUNT-1, because SURMOUNT-2 tested only 10 mg and 15 mg[1], so the arms are not perfectly matched populations. Read together, the label suggests that once weight loss is in this range, a few percentage points more or less doesn’t change the shedding risk much.

The label adds three facts that most hair-loss articles skip[1]:

  • The sex gap is very large. In the pooled trials, hair loss affected 7.1% of women versus 0.5% of men on Zepbound, and 1.3% of women versus 0% of men on placebo.
  • Nobody quit over it. No Zepbound-treated patient discontinued for hair loss; one placebo patient did.
  • The label itself links it to weight loss. Its wording is that hair-loss reactions “were associated with weight reduction,” not that the drug acts on hair.

For context, the Wegovy label reports hair loss in 3.3% of patients on semaglutide 2.4 mg versus 1% on placebo, and 5.8% at the newer 7.2 mg dose[12]. The full side-by-side lives on our GLP-1 hair loss overview and the Wegovy page; for the lower diabetes doses, see whether Ozempic causes hair loss.

Why Zepbound hits women so much harder

A 14-fold gap between women and men is the single most useful number on the label for setting expectations. If you are a woman losing weight quickly on Zepbound, your odds of noticing shedding during the trials were roughly 1 in 14; for men, closer to 1 in 200[1]. SURMOUNT-1 enrolled 68% women[1], so the overall 5% figure leans toward the female experience already.

The pattern matches what dermatologists see outside of drug trials. In a Korean single-center study of 140 people diagnosed with weight-loss-related telogen effluvium, 110 were women, and men in that cohort had lost weight significantly faster than women. The authors concluded that women and older adults are especially vulnerable even when their weight loss is no more severe than men’s[6].

Why rapid weight loss sheds hair

Most scalp hairs are growing at any moment, roughly 85%, with about 15% resting before they fall out. A significant physical stress can push a large share of growing hairs into the resting phase at once, and they shed together a few months later[7]. That delay is why people often blame whatever they changed most recently rather than the weight loss that started it. A dermatology commentary on GLP-1 drugs puts typical onset for this kind of shedding at about 3 months[8].

Zepbound produces that kind of stress through the size of the loss. In the Korean cohort, telogen effluvium appeared at an average weight loss of about 15%[6], and in SURMOUNT-1 the average loss was 15.0% at 5 mg and about 20% or more at 10 and 15 mg[2]. The same study put the average pace at 3.5 kg a month[6]. In SURMOUNT-1, losing 20.9% of a 105.6 kg average starting weight over 72 weeks works out to roughly 1.3 kg a month[1]. That is an average over the whole trial, and some months will run faster, which is why total loss and pace both belong in the conversation with your prescriber.

Is the drug doing something beyond weight loss? Nobody knows yet. A 2025 health-records study (Journal of the American Academy of Dermatology) reported, in its title, an increased risk of telogen effluvium with tirzepatide compared with other weight-loss medications[11], and the 2026 commentary calls the signal for tirzepatide and semaglutide the strongest in the class while stressing that causality has not been established[8].

Will it grow back, and how long does it take?

For telogen effluvium the outlook is good: the follicles are resting, not destroyed, so the shedding is non-scarring[7]. The expected course is that shedding stops once weight loss stops[8]. A resting hair stays in place for around 4 months before a new growing hair pushes it out[7], so regrowth shows up as short new hairs well before your ponytail feels thicker. No trial has measured how long recovery takes on Zepbound specifically, so treat any precise timeline you read online with caution.

When to call your prescriber or a dermatologist

  • Patches instead of all-over thinning. Telogen effluvium is diffuse[7]. Round bald spots point toward alopecia areata, which needs its own workup.
  • Redness, pain, scaling, or shiny smooth skin where hair used to be. That is not telogen effluvium and needs a dermatologist promptly.
  • Shedding that keeps going after your weight has been stable for months. The commentary’s advice is to identify the specific type of hair loss and refer to a dermatologist when appropriate[8].
  • Other symptoms alongside the shedding, such as unusual fatigue, feeling cold, or heavy periods. These are reasons to check thyroid and iron[7].

For the rest of the side-effect picture, see Zepbound side effects. The same molecule sold for type 2 diabetes is covered on the Mounjaro hair loss page, and how long GLP-1 fatigue and hair loss last covers the timeline across the class.

Our reviews

Providers that offer tirzepatide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

Shedding that has already started usually can't be switched off, but it tends to stop once weight loss levels off. What helps is not making it worse: eat enough protein, ask your prescriber about a slower dose escalation, get blood tests (iron, thyroid) before buying supplements, and don't stop Zepbound on your own. In SURMOUNT-4, people switched to placebo regained 14% of their weight within a year.
The ZEPBOUND label reports hair loss in 5% of patients on 5 mg, 4% on 10 mg and 5% on 15 mg, versus 1% on placebo, in the pooled SURMOUNT-1 and SURMOUNT-2 trials. It was much more common in women (7.1%) than men (0.5%), and no patient on Zepbound stopped treatment because of it.
Not reliably. The label shows nearly the same hair-loss rate at 5 mg (5%), 10 mg (4%) and 15 mg (5%). Hair loss tracks weight reduction, so the speed and amount of loss matter more than the milligrams. Any dose change is a decision for your prescriber.
In telogen effluvium, the usual cause, the follicles are resting rather than damaged, so the hair loss is non-scarring and is expected to stop once weight loss stops. New growth appears first as short hairs. Patchy, scarred or painful areas are different and need a dermatologist.
The label reports 7.1% of women versus 0.5% of men on Zepbound had hair loss. Dermatology studies of weight-loss-related shedding show the same pattern: in one cohort of 140 patients, 110 were women, and the authors concluded women are especially vulnerable even when their weight loss is no more severe than men's.
There is no good evidence that it does unless you are actually deficient. A systematic review found biotin helped only people with an underlying deficiency or disorder, and concluded there is not enough evidence to recommend it for healthy people.

References

  1. 1.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Sections 2, 6.1 (Hair Loss) and 14. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  2. 2.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024.
  3. 3.Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023. PMID: 37385275.
  4. 4.Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID: 38078870.
  5. 5.Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, Stefanski A, Griffin R. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. PMID: 39996356.
  6. 6.Kang DH, Kwon SH, Sim WY, Lew BL. Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Ann Dermatol. 2024. PMID: 39623615.
  7. 7.Hughes EC, Syed HA, Saleh D. Telogen Effluvium. StatPearls Publishing. 2024. PMID: 28613598.
  8. 8.Piraccini BM, Vañó-Galván S, Blume-Peytavi U, Ribet V, Mengeaud V. Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes. Dermatol Ther (Heidelb). 2026. PMID: 42249225.
  9. 9.Durusu Turkoglu IN, Turkoglu AK, Soylu S, Gencer G, Duman R. A comprehensive investigation of biochemical status in patients with telogen effluvium: Analysis of Hb, ferritin, vitamin B12, vitamin D, thyroid function tests, zinc, copper, biotin, and selenium levels. J Cosmet Dermatol. 2024. PMID: 39107936.
  10. 10.Patel DP, Swink SM, Castelo-Soccio L. A Review of the Use of Biotin for Hair Loss. Skin Appendage Disord. 2017. PMID: 28879195.
  11. 11.Neubauer Z, Ong MM, Singal A, Lipner SR. Increased risk of telogen effluvium with tirzepatide compared to other weight loss medications: A retrospective cohort TriNetX database study. J Am Acad Dermatol. 2025. PMID: 40848975.
  12. 12.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information, Section 6.1 (Hair Loss). DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

Does Wegovy Cause Hair Loss? What the FDA Label Says (2026)

Wegovy's label: hair loss in 3.3% on 2.4 mg vs 1% on placebo (4% of women, 0.9% of men), 5.8% on 7.2 mg. When shedding starts and what helps.

11 min read

Do GLP-1s Cause Hair Loss? What All 5 Labels Say (2026)

Wegovy and Zepbound list hair loss in 3–6% of adults vs 1% on placebo; Ozempic, Rybelsus and Mounjaro give no rate. Why it happens and what helps.

8 min read

Ozempic Hair Loss: What the Label and Diabetes Data Show (2026)

Ozempic's label lists hair loss only in postmarketing reports. What a 2026 type 2 diabetes study found, why Wegovy's rate is higher, and when to see a doctor.

10 min read

Does Semaglutide Cause Hair Loss? Ozempic vs Wegovy (2026)

Only Wegovy's label prints a semaglutide hair-loss rate (3.3% vs 1%). What Ozempic, Rybelsus and compounded semaglutide labels say, and what helps.

10 min read

GLP-1 + Finasteride or Minoxidil for Hair Loss: The Stacking Guide

GLP-1 telogen effluvium is real — 10-15% of patients shed during rapid weight loss. Stacking with finasteride 1 mg or topical minoxidil 5% can rescue regrowth. We review the published TE trials, finasteride PROPECIA pivotal, and the practical 6-month protocol.

12 min read

GLP-1 Side Effects Duration: Fatigue, Hair Loss, and How Long Everything Actually Lasts

Most GLP-1 nausea fades within 1 to 2 weeks at each dose step, peaking in the first 1 to 2 weeks after an increase. Fatigue was reported by about 11% on semaglutide versus 5% on placebo in the Wegovy label's pooled STEP 1-3 data. This guide covers how long fatigue, hair loss, and GI effects last.

11 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

From $69/mo

+ required membership

Get started →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

From $129/mo

starting price

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $129/mo

sale price

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →